Roadmap: helium ion therapy

Author:

Mairani Andrea,Mein Stewart,Blakely EleanorORCID,Debus Jürgen,Durante MarcoORCID,Ferrari Alfredo,Fuchs HermannORCID,Georg DietmarORCID,Grosshans David R,Guan FadaORCID,Haberer Thomas,Harrabi Semi,Horst Felix,Inaniwa Taku,Karger Christian PORCID,Mohan RadheORCID,Paganetti HaraldORCID,Parodi KatiaORCID,Sala PaolaORCID,Schuy Christoph,Tessonnier Thomas,Titt Uwe,Weber Ulrich

Abstract

Abstract Helium ion beam therapy for the treatment of cancer was one of several developed and studied particle treatments in the 1950s, leading to clinical trials beginning in 1975 at the Lawrence Berkeley National Laboratory. The trial shutdown was followed by decades of research and clinical silence on the topic while proton and carbon ion therapy made debuts at research facilities and academic hospitals worldwide. The lack of progression in understanding the principle facets of helium ion beam therapy in terms of physics, biological and clinical findings persists today, mainly attributable to its highly limited availability. Despite this major setback, there is an increasing focus on evaluating and establishing clinical and research programs using helium ion beams, with both therapy and imaging initiatives to supplement the clinical palette of radiotherapy in the treatment of aggressive disease and sensitive clinical cases. Moreover, due its intermediate physical and radio-biological properties between proton and carbon ion beams, helium ions may provide a streamlined economic steppingstone towards an era of widespread use of different particle species in light and heavy ion therapy. With respect to the clinical proton beams, helium ions exhibit superior physical properties such as reduced lateral scattering and range straggling with higher relative biological effectiveness (RBE) and dose-weighted linear energy transfer (LETd) ranging from ∼4 keV μm−1 to ∼40 keV μm−1. In the frame of heavy ion therapy using carbon, oxygen or neon ions, where LETd increases beyond 100 keV μm−1, helium ions exhibit similar physical attributes such as a sharp lateral penumbra, however, with reduced radio-biological uncertainties and without potentially spoiling dose distributions due to excess fragmentation of heavier ion beams, particularly for higher penetration depths. This roadmap presents an overview of the current state-of-the-art and future directions of helium ion therapy: understanding physics and improving modeling, understanding biology and improving modeling, imaging techniques using helium ions and refining and establishing clinical approaches and aims from learned experience with protons. These topics are organized and presented into three main sections, outlining current and future tasks in establishing clinical and research programs using helium ion beams—A. Physics B. Biological and C. Clinical Perspectives.

Publisher

IOP Publishing

Subject

Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology

Reference245 articles.

1. Recent developments in Geant4;Allison;Nucl. Instrum. Methods Phys. Res. A,2016

2. Developments of the nuclear reaction and fragmentation models in FLUKA for ion collisions at therapeutic energies;Arico,2019

3. Investigation of mixed ion fields in the forward direction for 220.5 mev/u helium ion beams: comparison between water and pmma targets;Arico;Phys. Med. Biol.,2017

4. Late contrast enhancing brain lesions in proton-treated patients with low-grade glioma: clinical evidence for increased periventricular sensitivity and variable RBE;Bahn;Int. J. Radiat. Oncol. Biol. Phys.,2020

5. The FLUKA code: an accurate simulation tool for particle therapy;Battistoni;Front. Oncol.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3